ID: ALA4175734

Max Phase: Preclinical

Molecular Formula: C19H16BrNO5

Molecular Weight: 418.24

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOc1ccc2oc(-c3cc(Br)cc4c3OCOC4)c(N)c(=O)c2c1

Standard InChI:  InChI=1S/C19H16BrNO5/c1-2-24-12-3-4-15-13(7-12)17(22)16(21)19(26-15)14-6-11(20)5-10-8-23-9-25-18(10)14/h3-7H,2,8-9,21H2,1H3

Standard InChI Key:  MXLOXXCYFYZZDX-UHFFFAOYSA-N

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 418.24

Molecular Weight (Monoisotopic): 417.0212

AlogP: 4.07

#Rotatable Bonds: 3

Polar Surface Area: 83.92

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa:

CX LogP: 2.71

CX LogD: 2.71

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.69

Np Likeness Score: -0.16

References

1. Yang K, Nong K, Gu Q, Dong J, Wang J..  (2018)  Discovery of N-hydroxy-3-alkoxybenzamides as direct acid sphingomyelinase inhibitors using a ligand-based pharmacophore model.,  151  [PMID:29649738] [10.1016/j.ejmech.2018.03.065]

2. Yang K, Yu J, Nong K, Wang Y, Niu A, Chen W, Dong J, Wang J..  (2020)  Discovery of Potent, Selective, and Direct Acid Sphingomyelinase Inhibitors with Antidepressant Activity.,  63  (3): [PMID:31944697] [10.1021/acs.jmedchem.9b00739]

Source

Source(1):

• Scientific Literature